Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus chemotherapy conversion therapy for unresectable locally advanced esophageal squamous cell carcinoma
ChiCTR2400093272Phase 4Not yet recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Dec 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab, paclitaxel and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Liaoning Province Cancer Hospital. Primary endpoint: R0 resection rate. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
tislelizumabpaclitaxelcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2400093272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093272.